An early indicator of drug success: Top journal Selectivity Index

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 93-98

  Kissin, Igor ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

'me too' drugs; Bibliometrics; Pharmaceutical market; Scientometrics

Indexed keywords

ACICLOVIR; ALFENTANIL; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; CAPTOPRIL; CELECOXIB; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; FELODIPINE; FOSCARNET; GABAPENTIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; MOEXIPRIL; NEW DRUG; OMEGA CONOTOXIN MVIIA; PREGABALIN; PROPRANOLOL; PROTON PUMP INHIBITOR; REMIFENTANIL; RNA DIRECTED DNA POLYMERASE INHIBITOR; SUMATRIPTAN; TOPIRAMATE; TRAMADOL; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

BIBLIOMETRICS; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS (TOPIC); PREDICTION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; STATISTICAL ANALYSIS; TOP JOURNAL SELECTIVITY INDEX;

'ME-TOO' DRUGS; BIBLIOMETRICS; PHARMACEUTICAL MARKET; SCIENTOMETRICS;

BIBLIOMETRICS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PERIODICALS AS TOPIC; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 84873959913     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S37324     Document Type: Review

References (16)

1. Agarwal P, Searls DB. Can literature analysis identify innovation drivers in drug discovery? Nat Rev Drug Discov. 2009;8:865-877.
2. Bordons M, Bravo C, Barrington S. Time-tracking of the research profile of a drug using bibliometric tools. J Am Soc Inf Sci Technol. 2004;55: 45-61.
3. Windsor DA. Could bibliometric data be used to predict the clinical success of drugs? J Doc. 1976;32:174-181.
4. Windsor DA. Bibliometrics and drugs. J Chem Inform Comput Sci. 1980;20(4):255.
5. Kissin I. Can a bibliometric indicator predict the success of an analgesic? Scientometrics. 2011;86:785-795.
6. Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg. 2010;110:780-789.
7. Stafford S, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative effectiveness information into FDA labeling. N Eng J Med. 2009;361:1230-1233.
8. Kissin I, Bradley EL Jr. Top journal selectivity index: is it acceptable for drugs beyond the field of analgesia? Scientometrics. 2011;88: 589-597.
9. Koenig MED. Determinants of expert judgment of research performance. Scientometrics. 1982;4:261-278.
10. Gagne JJ, Choudhry NK. How many "me-too" drugs is too many? JAMA. 2011;305:711-721.
11. Kissin I, Bradley EL Jr. Top journal selectivity index and "me-too" drugs. Scientometrics. 2012;91:131-142.
12. Cohen FJ. Entry order as a consideration for innovation strategies. Nat Rev Drug Discov. 2006;5:285-293.
13. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to do About It. New York, NY: Random House; 2004.
14. Curfman GD, Morrissey S, Drazen JM. Products at risk. N Engl J Med. 2010;363:176.
15. Pekarsky B. Should financial incentives be used to differentially reward "me-too" and innovative drugs? Pharmacoeconomics. 2010;28:1-17.
16. DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nat Rev Drug Discov. 2011;10:23-27.